Biofrontera (BFRI) Common Equity (2020 - 2025)

Biofrontera's Common Equity history runs 6 years deep, the most recent figure standing at $10.5 million for Q4 2025.

• In Q4 2025, Common Equity rose 136.41% year-over-year to $10.5 million; the TTM figure through Dec 2025 stood at $10.5 million (up 136.41% YoY), while the FY2025 annual figure was $10.5 million, up 136.41% from the prior year.
• Common Equity was $10.5 million for Q4 2025 at Biofrontera, up from -$2.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $23.9 million in Q4 2022 to a low of -$17.4 million in Q3 2021.
• Historically, Common Equity has averaged $6.2 million across 5 years, with a median of $5.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 1359.72% in 2022, then slumped 146.67% in 2025.
• A 5-year view of Common Equity shows it stood at $11.3 million in 2021, then soared by 110.6% to $23.9 million in 2022, then slumped by 79.93% to $4.8 million in 2023, then declined by 7.51% to $4.4 million in 2024, then jumped by 136.41% to $10.5 million in 2025.
• The last three Common Equity figures came in at $10.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$4.7 million (Q2 2025), per Business Quant data.